Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme.
Vanita R ArodaRobert BauerErik ChristiansenMartin HaluzíkKlaus KallenbachEduard MontanyaJulio RosenstockJuris J MeierPublished in: Diabetes, obesity & metabolism (2022)
Oral semaglutide demonstrated consistently greater HbA1c and body weight reductions across a range of patient characteristics, with greater HbA1c reductions seen at higher baseline HbA1c levels.